/
Hematology
Immune Thrombocytopenia
58
Pipeline Programs↗
85
Active Trials↗
51
Companies Involved↗
Immune Thrombocytopenia is a moderately active landscape with 58 programs across 51 companies. The most active players are Argenx, Novartis, Sanofi. 12 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 16
Phase 225
Phase 312
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
40 of 49 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 93% of 58 pipeline programs.
Analysis
Trial Status
201
clinical trials
Completed55 · 27%
Recruiting54 · 27%
Unknown status41 · 20%
Not yet recruiting18 · 9%
Active, not recruiting13 · 6%
Withdrawn11 · 5%
Other9 · 4%
Clinical Trials
Trial Activity
201 trials
Efficacy and Safety of Multi-Target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia: A Prospective, Single-arm, Multicenter, Exploratory Trial
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Approved·NCT07788456·38 enrolled
Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
Recruiting·—·N/A·NCT06973356·18 enrolled
Page 1 of 14
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)